“Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S22. doi:10.25251/skin.2.supp.22.